FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089158892> ?p ?o ?g. }

• W3089158892 endingPage "95" @default.
• W3089158892 startingPage "87" @default.
• W3089158892 abstract "Goal of the study. To study particular features of the immune status in microbial eczema and erysipelas patients in the process of a complex immune modulating therapy with Xymedone®. Materials and methods. the study involved 45 microbial eczema patients and 31 patients with a combined form of microbial eczema and erysipelas (the study group) and healthy subjects (60 and 50 subjects). All of the subjects underwent immunology examinations of their cell and humoral immunity prior to and after the pathogenetic treatment with Xymedone®. The traditional therapy of a combined course of microbial eczema and erysipelas comprised the following basic treatment: third-generation cephalosporins (ceftriaxone): 1.0 g a day for 10 days; second-generation antihistamine drugs (peroral loratadine 10 mg once a day for 10 days) and ascorbic acid 0.5 g a day for 14 days. topical treatment comprised antiseptic agents (furacilin solution 1:1000) at the acute stage, emulsions and creams (depending on the disease stage): topical mometasone furoate 0.1% twice a day for 14 days. The patients receiving Xymedone were treated in the dose of 0.25 g, one pill tree times a day for 14 days. The patients underwent an immunology study using the Sysmex Corporation XT2000 automated analyzer at the CityLab laboratory centers in the city of Kazan. Key findings. Prior to the pathogenic therapy, a high level of CD4 (T helpers) and reduced level of the immunoregulatory index (T helpers to T suppressors ratio) (IRI) was revealed in the microbial eczema patients. Ig А and Ig G concentrations were reliably increased. According to a study of immunology indices, the pathogenic therapy using Xymedone® normalized the number of peripheral blood leucocytes and reliably increased the IRI (p < 0.001) in 45 microbial eczema patients. Prior to the pathogenic therapy, a reduced level of CD3 and CD4 cells was revealed in patients with a combined form of microbial eczema and erysipelas; the levels of CD8 and NK cells (CD16) were also reduced. Ig А, Ig M and IgG concentrations were reliably reduced. According to a study of immunology indices, the pathogenic therapy using Xymedone® increased the concentration of CD3 and CD4 cells. Conclusion. Xymedone®, an immune modulating drug, administered as a part of a combination therapy of microbial eczema patients and patients with a combined form of microbial eczema and erysipelas is a form of supplementary pathogenic I therapy; the treatment improved the cellular and humoral immunity indices." @default.
• W3089158892 created "2020-10-01" @default.
• W3089158892 creator A5006375467 @default.
• W3089158892 creator A5019597220 @default.
• W3089158892 creator A5027085871 @default.
• W3089158892 creator A5033717876 @default.
• W3089158892 creator A5074210135 @default.
• W3089158892 creator A5077879998 @default.
• W3089158892 date "2016-04-24" @default.
• W3089158892 modified "2023-09-26" @default.
• W3089158892 title "Particular features of the immune status in microbial eczema and erysipelas patients: a therapeutic method" @default.
• W3089158892 cites W1984840936 @default.
• W3089158892 cites W2128948746 @default.
• W3089158892 cites W2165848565 @default.
• W3089158892 doi "https://doi.org/10.25208/0042-4609-2016-92-2-87-95" @default.
• W3089158892 hasPublicationYear "2016" @default.
• W3089158892 type Work @default.
• W3089158892 sameAs 3089158892 @default.
• W3089158892 citedByCount "1" @default.
• W3089158892 countsByYear W30891588922023 @default.
• W3089158892 crossrefType "journal-article" @default.
• W3089158892 hasAuthorship W3089158892A5006375467 @default.
• W3089158892 hasAuthorship W3089158892A5019597220 @default.
• W3089158892 hasAuthorship W3089158892A5027085871 @default.
• W3089158892 hasAuthorship W3089158892A5033717876 @default.
• W3089158892 hasAuthorship W3089158892A5074210135 @default.
• W3089158892 hasAuthorship W3089158892A5077879998 @default.
• W3089158892 hasBestOaLocation W30891588921 @default.
• W3089158892 hasConcept C126322002 @default.
• W3089158892 hasConcept C16005928 @default.
• W3089158892 hasConcept C203014093 @default.
• W3089158892 hasConcept C2776804153 @default.
• W3089158892 hasConcept C2779990042 @default.
• W3089158892 hasConcept C2781348165 @default.
• W3089158892 hasConcept C71924100 @default.
• W3089158892 hasConcept C8891405 @default.
• W3089158892 hasConceptScore W3089158892C126322002 @default.
• W3089158892 hasConceptScore W3089158892C16005928 @default.
• W3089158892 hasConceptScore W3089158892C203014093 @default.
• W3089158892 hasConceptScore W3089158892C2776804153 @default.
• W3089158892 hasConceptScore W3089158892C2779990042 @default.
• W3089158892 hasConceptScore W3089158892C2781348165 @default.
• W3089158892 hasConceptScore W3089158892C71924100 @default.
• W3089158892 hasConceptScore W3089158892C8891405 @default.
• W3089158892 hasIssue "2" @default.
• W3089158892 hasLocation W30891588921 @default.
• W3089158892 hasOpenAccess W3089158892 @default.
• W3089158892 hasPrimaryLocation W30891588921 @default.
• W3089158892 hasRelatedWork W1932241263 @default.
• W3089158892 hasRelatedWork W1988902089 @default.
• W3089158892 hasRelatedWork W2083261943 @default.
• W3089158892 hasRelatedWork W2088221377 @default.
• W3089158892 hasRelatedWork W2112318593 @default.
• W3089158892 hasRelatedWork W2768682223 @default.
• W3089158892 hasRelatedWork W3147893165 @default.
• W3089158892 hasRelatedWork W3215948423 @default.
• W3089158892 hasRelatedWork W4211081403 @default.
• W3089158892 hasRelatedWork W4297184974 @default.
• W3089158892 hasVolume "92" @default.
• W3089158892 isParatext "false" @default.
• W3089158892 isRetracted "false" @default.
• W3089158892 magId "3089158892" @default.
• W3089158892 workType "article" @default.